ISSN 1662-4009 (online)

ey0019.11-9 | New predictors of obesity development | ESPEYB19

11.9. Fat mass and fat-free mass track from infancy to childhood: New insights in body composition programming in early life

IA van Beijsterveldt , KS de Fluiter , LM Breij , M van der Steen , ACS Hokken-Koelega

joelh@broadinstitute.org Obesity (Silver Spring). 2021 Nov;29(11):1899–1906. doi: 10.1002/oby.23271. Epub 2021 Sep 21. https://pubmed.ncbi.nlm.nih.gov/34549538/Brief Summary: This longitudinal study assessed body composition in a cohort of children at ages 1, 3, and 6 months and 4 years (n...

ey0015.4-3 | Important for clinical practice | ESPEYB15

4.3 Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study

M van der Steen , GF Kerkhof , CCJ Smeets , ACS Hokken-Koelega

To read the full abstract: Lancet Diabetes Endocrinol 2017;5:975-985Whereas most SGA children experience spontaneous catch-up growth leading to the achievement of normal adult height, approximately 10% remain short and are candidates for GH therapy. SGA subjects have increased cardio-metabolic disease risk [17] and the effects of GH treatment on blood...

ey0020.2-4 | Important for Clinical Practice | ESPEYB20

2.4. Childhood growth hormone treatment and metabolic and cardiovascular risk in adults born small for gestational age after growth hormone cessation in the Netherlands: a 12-year follow-up study

WJ Goedegebuure , M van der Steen , CCJ Smeets , ACS Hokken-Koelega

Brief summary: In this longitudinal study, the authors investigated the metabolic and cardiovascular health profile of 167 adults born SGA and previously treated with rhGH during a period of 12 years after therapy discontinuation. No relevant differences were found in treated SGA subjects compared with untreated SGA adults or adults born appropriate for gestational age (AGA), thus suggesting long-term metabolic and cardiovascular safety of rhGH treatment in short SGA children....

ey0021.4-5 | Important for Clinical Practice | ESPEYB21

4.5. Cerebrovascular abnormalities in adults born SGA at 12 years after growth hormone cessation compared to controls

DJ Dorrepaal , WJ Goedegebuure , L Smagge , M van der Steen , A van der Lugt , ACS Hokken-Koelega

Brief Summary: This single-center, prospective study used brain MRI to assess the prevalence of cerebrovascular abnormalities in a large cohort of adult patients born SGA and treated with GH during childhood, 12 years after rhGH treatment cessation. GH treatment was not associated with a higher incidence of aneurysms, intracerebral hemorrhages, microbleeds or other vascular abnormalities.The French population-based cohort of the Safety and Appropriatenes...

ey0021.4-6 | Important for Clinical Practice | ESPEYB21

4.6. Clinical characteristics of pathogenic ACAN variants and 3-year response to growth hormone treatment: real-world data

JS Renes , AMJ Reedijk , M Losekoot , SG Kant , M Van der Steen , DCM Van der Kaay , ACS Hokken-Koelega , HA Van Duyvenvoorde , C de Bruin

Brief Summary: This study describes the clinical characteristics of pathogenic variants in the ACAN gene and the response to rhGH treatment over three years in children with a heterozygous ACAN variant. The results indicate that rhGH therapy may be considered to reduce the height deficit in these patients, particularly in prepubertal children with ACAN deficiency.Aggrecan is the major proteoglycan of the cartilage growth plate. Homozygo...